CClinicalTrials.gg
RecruitingNCT06465004Updated Jun 21, 2024

Pilot Trial: Bioavailability Animal vs. Plant Protein Drink

An interventional study of Consumption of protein - rich drink in Nutrition, Healthy and Leucine Sensitivity, sponsored by ETH Zurich. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by ETH Zurich · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

A pilot study is being conducted to compare a new plant-based protein drink to commercially available animal-based protein drinks. The goal is to assess if the plant-based drink delivers amino acids to the bloodstream as effectively as the animal-based drinks, potentially offering a viable option for those on plant-based diets.

The study will involve approximately 12 healthy adults aged 18-40. Each participant will try all three drinks (the new plant-based drink, a commercial animal-based drink, and another animal-based recipe) on separate days in a randomized order. Before and after (30, 60, and 90 minutes) consuming each drink, a small blood sample will be drawn to measure amino acid levels (leucine).

By comparing the results, the investigators hope to determine if the plant-based drink can match the effectiveness of animal-based protein drinks in delivering essential nutrients. This research could contribute to the development of sustainable and nutritious plant-based protein alternatives.

02

Conditions studied

  • Nutrition, Healthy
  • Leucine Sensitivity

Browse trials for

Keywords

  • Leucin
  • Plant-based
  • Animal-based
  • Bioavailability
03

In context

Hypersensitivity

1,916 studies on the registry are indexed under Hypersensitivity; 265 are open to participants now.

This study's planned enrollment of 12 is below the median of 57 across 1,384 interventional studies indexed under Hypersensitivity.

Browse Hypersensitivity studies →

Lead sponsor

ETH Zurich is the lead sponsor of 19 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Gender: male and female
  • Age: 18-40 years
  • Signed written informed consent

Exclusion criteria

Exclusion criteria

  • Smoking history
  • Cardiovascular diseases
  • BMI > 35 kg/m2
  • Caffeine consumption \< 1 day before the study participation
  • Allergies: Soy, Peas, Milk, Lactose, Fructose
  • High intensity exercise \<2 days before study participation
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Active comparator
    Animal-based A

    A commercially available high protein drink, based on animal proteins (Fresubin Protein Energy)

    Dietary Supplement: Consumption of protein - rich drink

  • Active comparator
    Animal-based B

    A homemade drink containing animal-based proteins, using a specific animal-based protein isolate mix.

    Dietary Supplement: Consumption of protein - rich drink

  • Active comparator
    Plant-based A

    A homemade drink containing plant-based proteins, formulated to have the same macronutrient content as the animal-based drinks.

    Dietary Supplement: Consumption of protein - rich drink

Interventions

  • Dietary supplementConsumption of protein - rich drink

    The participants will drink on of three protein - rich drinks

06

What researchers measure

Primary outcomes

  1. leucine content in the blood

    Assessment of leucine content in blood before and 30-60-90 min after consumption of drink

    Time frame: 4 hours

07

Study locations

1 of 1 sites recruiting
  • SLA - ETH Zurich
    Schwerzenbach, Zurich 8603, Switzerland
    Recruiting
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Apr 22, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06465004
Lead sponsor
ETH Zurich
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Jun 8, 2024
Primary completion
Jun 28, 2024 (estimated)
Completion
Aug 30, 2024 (estimated)
Last update
Jun 21, 2024

Study contacts

Gommaar D'Hulst, PhD
Contact
gommaar-dhulst@ethz.ch
+41786624474
Gommaar D'Hulst, PhD
principal investigator · ETH Zurich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion